Royalty Pharma Announces $500M R&D Co-Funding Agreement with Johnson & Johnson
Royalty Pharma (RPRX) announced a research and development co-funding agreement with Johnson & Johnson (JNJ) for a total of $500M in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ-4804 is a novel co-antibody therapy that blocks the complementary interleukin-23 and tumor necrosis factor pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases.
